Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.

European journal of neurology - 1 Mar 2018

Gundapaneni B K, Sultan M B, Keohane D J, Schwartz J H

Abstract excerpt

BACKGROUND AND PURPOSE: To better characterize the effects of tafamidis in non-Val30Met patients with transthyretin familial amyloid polyneuropathy, this post hoc analysis compared the neurological results from a 12-month, open-label study of non-Val30Met versus Val30Met patients at month 12 from the 18-month, double-blind, placebo-controlled registration study. A baseline covariate adjusted analysis was used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Amyloid Neuropathies, Familial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Double-Blind Method

Share to Genotype

Share to Lower Extremity

Share to Mutation

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 29115008
DOI: 10.1111/ene.13510
PMCID: PMC5838526

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.PMID 29115008Read ↗

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.Semantic proximity Read ↗

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.Semantic proximity Read ↗

Tafamidis for transthyretin amyloidosis.Semantic proximity Read ↗

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.Semantic proximity Read ↗

Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial.Semantic proximity Read ↗

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.Semantic proximity Read ↗

Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.Semantic proximity Read ↗

Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review.Semantic proximity Read ↗

Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France.Semantic proximity Read ↗

A Study of Familial Amyloid Polyneuropathy Induced by the TTR Val30Leu Mutation in China.Semantic proximity Read ↗

Real-World Effectiveness and Clinical Predictors of Response to First-Generation TTR Silencers in Variant ATTR Amyloidosis with PolyneuropathySemantic proximity Read ↗

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.